Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6.3% – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares dropped 6.3% during trading on Friday . The company traded as low as $30.94 and last traded at $31.3110. Approximately 525,588 shares changed hands during trading, a decline of 60% from the average daily volume of 1,315,334 shares. The stock had previously closed at $33.42.

Key Stories Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA resumed review of deramiocel and set an August decision window, reviving the pathway for approval and reducing some regulatory uncertainty. Capricor Shares Rise as FDA Sets August Decision Date for Rejected Duchenne Therapy
• Positive Sentiment: Late-breaking HOPE-3 Phase 3 data presented at the 2026 MDA conference showed significant functional benefits for deramiocel in Duchenne muscular dystrophy — a clinical readout that supports the therapy’s commercial potential if approved. HOPE-3 Data Press Release
• Positive Sentiment: HC Wainwright reiterated a Buy rating on CAPR, which can provide support from buy-side interest and signal confidence to some investors. HC Wainwright Reiterates Buy Rating for Capricor Therapeutics
• Neutral Sentiment: Company filed its fourth-quarter and full-year 2025 results and provided a corporate update; the release contains financial details and operational commentary investors will parse for runway and milestones. Q4 & Full-Year 2025 Results
• Neutral Sentiment: Q4 2025 earnings call transcript and supplemental materials are available for detailed management commentary and Q&A — useful for assessing guidance, cash runway and commercialization planning. Earnings Call Transcript
• Neutral Sentiment: News outlets flagged “earnings on deck” coverage following the FDA review resumption — media attention can amplify both upside and downside moves depending on follow-up items. Investing.com Coverage
• Neutral Sentiment: Recent short-interest reports show anomalous “0 shares” figures and a 0.0 days-to-cover metric — likely data noise rather than a material shift in short positioning. (Multiple short-interest updates posted March 11–12.)
• Negative Sentiment: Q4 EPS missed consensus: CAPR reported a loss of ($0.62) vs. analysts’ ($0.51) estimate. An EPS miss amid a biotech story often triggers immediate selling as investors re-price near-term execution and funding risk. MarketBeat Earnings Coverage

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on CAPR shares. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. B. Riley Financial reiterated a “buy” rating and issued a $50.00 price objective (up from $21.00) on shares of Capricor Therapeutics in a report on Monday, December 15th. Piper Sandler reissued an “overweight” rating and set a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday. iA Financial set a $48.00 price target on Capricor Therapeutics in a research note on Wednesday, December 3rd. Finally, Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Capricor Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $44.91.

Capricor Therapeutics Trading Down 7.3%

The firm has a market capitalization of $1.71 billion, a P/E ratio of -17.21 and a beta of 0.37. The business’s fifty day moving average is $25.66 and its 200 day moving average is $16.35.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, March 18th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, sell-side analysts predict that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CAPR. SB Capital Management Inc acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at $11,544,000. Creek Drive Management Group LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth about $1,039,000. Ikarian Capital LLC lifted its stake in Capricor Therapeutics by 118.4% during the fourth quarter. Ikarian Capital LLC now owns 578,015 shares of the biotechnology company’s stock valued at $16,682,000 after buying an additional 313,373 shares in the last quarter. Virtus Investment Advisers LLC boosted its holdings in shares of Capricor Therapeutics by 25.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,224 shares of the biotechnology company’s stock worth $295,000 after buying an additional 2,061 shares during the period. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in Capricor Therapeutics in the 4th quarter worth approximately $384,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.